State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Efficacy and Safety of Asciminib in Ph+ CML

Luke Fletcher

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes Among Pat…

Insights from 2023 ASH Annual Meeting

E. Atallah

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

SOHO 2023 Eleventh Annual Meeting

N. Cross

Experts Discuss How They Use Asciminib in Their CML Practice

MyCancerHaven

R. Vij, J. Zeidner

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

CRS and ICANS With BiTEs in ALL - How to Manage With Dose Adjustments

Elias Jabbour

SOHO 2023: CML - Are We Doing It Right?

SOHO 2023 Eleventh Annual Meeting

J. Cortés

Clinically-Relevant Updates in ALL in Adults

Insights from 2023 ASH Annual Meeting

R. Cassaday

Updated Results from the BLAST and TOWER Studies: Safety and Efficac…

Michael Burke

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

SOHO 2023: Rational TKI Choice in CML

SOHO 2023 Eleventh Annual Meeting

M. Deininger

How Are Targeted Therapies Redefining the Treatment Paradigm in ALL …

SOHO Brazil 2024

J. Burger